<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://elea.unisa.it/xmlui/handle/10556/1614">
<title>Translational Medicine @ UniSa. Volume 11 (jan.-apr. 2015)</title>
<link>http://elea.unisa.it/xmlui/handle/10556/1614</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://elea.unisa.it/xmlui/handle/10556/1655"/>
<rdf:li rdf:resource="http://elea.unisa.it/xmlui/handle/10556/1654"/>
<rdf:li rdf:resource="http://elea.unisa.it/xmlui/handle/10556/1653"/>
<rdf:li rdf:resource="http://elea.unisa.it/xmlui/handle/10556/1652"/>
</rdf:Seq>
</items>
<dc:date>2026-04-14T14:56:29Z</dc:date>
</channel>
<item rdf:about="http://elea.unisa.it/xmlui/handle/10556/1655">
<title>Three Dimensional Myocardial Deformation and Diagnosis of Stable Coronary Artery Disease</title>
<link>http://elea.unisa.it/xmlui/handle/10556/1655</link>
<description>Three Dimensional Myocardial Deformation and Diagnosis of Stable Coronary Artery Disease
To date, only one third of patients, with stable
angina, undergoing coronary angiography demonstrated
obstructive coronary artery disease (CAD). Thus,
identifying high sensitivity and specificity, low-cost, non
invasive tests is crucial. Here we present the case of a
patient, at a high risk of CAD, undergoing coronary
angiography because of positive exercise test and stress
imaging results, with non obstructive coronary artery
disease at angiography, confirmed by FFR. Interestingly,
3D speckle tracking, performed before angiography,
assessed normal left ventricle deformation, predicting the
absence of severe coronary artery lesions.
</description>
<dc:date>2015-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://elea.unisa.it/xmlui/handle/10556/1654">
<title>Glomus Tumor of the Thenar Eminence in Neurofibromatosis Type 1: Case Report and Literature Review</title>
<link>http://elea.unisa.it/xmlui/handle/10556/1654</link>
<description>Glomus Tumor of the Thenar Eminence in Neurofibromatosis Type 1: Case Report and Literature Review
Neurofibromatosis type 1 (NF1) is a disease characterized by increased tumorigenesis susceptibility, caused by mutations of the oncosuppressor gene NF1. The glomus tumor (GT) is a rare, very painful mesenchymal neoplasm, arising from the glomus body. In recent years, it has been highlighted the association between NF1 and GT. We report a case of a man aged 65 years, suffering from NF1, with intense pain at the thenar eminence of the right hand, successfully treated with the excision of the mass.
</description>
<dc:date>2015-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://elea.unisa.it/xmlui/handle/10556/1653">
<title>Heart Failure in a Dedicated Outpatient Clinic: Results after 58 Month Follow-Up. Can it be Enough?</title>
<link>http://elea.unisa.it/xmlui/handle/10556/1653</link>
<description>Heart Failure in a Dedicated Outpatient Clinic: Results after 58 Month Follow-Up. Can it be Enough?
Incidence of chronic heart failure (HF) is
rapidly increasing, approaching a 10 per 1000 rate after
65 years of age. In the last decades, despite
pharmacological, interventional and supportive
innovations, HF prognosis remained poor, with about
30% of death within one year from the diagnosis.
Current guidelines recommend for these patients
management programs providing follow-up through
dedicated outpatient clinic. Limits of these programs
are represented by great difficulties in getting patients
adherence, being still too elevated the rate of
abandonments. In this paper, we analyzed the impact of
58 months of activity in our dedicated to heart failure
outpatient clinic on mortality, hospitalization and
abandonment rate. 477 HF patients (346 M, 72.5%,
mean age 69.6 years) were enrolled. Mean follow-up
and visit were 18.2 and 2.6 months respectively. Total
mortality rate was 11.5%, 4% of patients per year.
Total hospitalizations for acute HF were 212 and,
among all patients left in follow-up, the number of
hospitalizations for acute de-compensation
significantly decreased from 0.49/patient/year before
enrollment to 0.29/patient/year during follow-up
(p=0.015). Patients who abandoned outpatient clinic
were 94 (19%, 1 abandonment every 23 days), mostly
observed over the first months of activity. In
conclusion, our patients experienced a major decrease
in rates of acute de-compensation and need of inhospital
admissions.
</description>
<dc:date>2015-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://elea.unisa.it/xmlui/handle/10556/1652">
<title>A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno</title>
<link>http://elea.unisa.it/xmlui/handle/10556/1652</link>
<description>A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno
Abacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLA-B*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLA-B*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.
</description>
<dc:date>2015-01-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
